|
PPP2R5E expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.02159999962426E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.95011999999384E-05 |
| Normal-vs-Stage2 |
7.168400E-04 |
| Normal-vs-Stage3 |
2.24009999993946E-07 |
| Normal-vs-Stage4 |
5.59920000364755E-08 |
| Stage1-vs-Stage2 |
9.886800E-01 |
| Stage1-vs-Stage3 |
1.056010E-01 |
| Stage1-vs-Stage4 |
2.325500E-02 |
| Stage2-vs-Stage3 |
2.514800E-01 |
| Stage2-vs-Stage4 |
5.412100E-02 |
| Stage3-vs-Stage4 |
3.172600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.44060000045943E-07 |
| Normal-vs-AfricanAmerican |
1.254110E-02 |
| Normal-vs-Asian |
3.230600E-04 |
| Caucasian-vs-AfricanAmerican |
5.128600E-01 |
| Caucasian-vs-Asian |
7.570400E-01 |
| AfricanAmerican-vs-Asian |
7.093400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.53469999988987E-07 |
| Normal-vs-Female |
1.19290000000216E-06 |
| Male-vs-Female |
2.814000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.556900E-04 |
| Normal-vs-Age(41-60Yrs) |
3.49050000014728E-08 |
| Normal-vs-Age(61-80Yrs) |
1.25159999997404E-06 |
| Normal-vs-Age(81-100Yrs) |
1.282390E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.499700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.761560E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.552000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.063600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.486400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.823000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.540600E-01 |
| Classical-VS-Follicular |
2.864800E-01 |
| Classical-VS-Other |
3.528200E-01 |
| Classical-VS-Normal |
1.63628999999554E-05 |
| Tall-VS-Follicular |
7.006000E-01 |
| Tall-VS-Other |
7.060200E-01 |
| Tall-VS-Normal |
8.30030000000814E-05 |
| Follicular-VS-Other |
6.006000E-01 |
| Follicular-VS-Normal |
2.20479999999412E-05 |
| Other-VS-Normal |
9.918800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.73549999996581E-07 |
| Normal-vs-N1 |
2.49650000005985E-07 |
| N0-vs-N1 |
1.069180E-01 |
|
|
